AnaptysBio
NASDAQ · ANAB·San Diego, CA·Small-cap·Phase 2
Clinical-stage biotech developing antibody therapeutics for inflammation. Rosnilimab is a potentially first-in-class PD-1 agonist mAb in Phase 2 for rheumatoid arthritis and ulcerative colitis. ANB032 (anti-BTLA) is in Phase 2 for atopic dermatitis. Also generates royalties on Jemperli (GSK).
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| AnaptysBio Corporate Presentation — April 2026 | Corporate overview | March 26, 2026 | 66 |